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Abstract: Immune thrombocytopenia (ITP) is an acquired bleeding autoimmune disorder 
characterized by a markedly decreased blood platelet count. The disorder is variable, frequently 
having an acute onset of limited duration in children and a more chronic course in adults. 
A number of therapeutic agents have demonstrated efﬁ  cacy in increasing the platelet counts in 
both children and adults. Anti-RhD immunoglobulin (anti-D) is one such agent, and has been 
successfully used in the setting of both acute and chronic immune thrombocytopenia. In this 
report we review the use of anti-D in the management of ITP. While the FDA-approved dose 
of 50 mg/kg has documented efﬁ  cacy in increasing platelet counts in approximately 80% of 
children and 70% of adults, a higher dose of 75 μg/kg has been shown to result in a more rapid 
increase in platelet count without a greater reduction in hemoglobin. Anti-D is generally inef-
fective in patients who have failed splenectomy. Anti-RhD therapy has been shown capable of 
delaying splenectomy in adult patients, but does not signiﬁ  cantly increase the total number of 
patients in whom the procedure can be avoided. Anti-D therapy appears to inhibit macrophage 
phagocytosis by a combination of both FcR blockade and inﬂ  ammatory cytokine inhibition of 
platelet phagocytosis within the spleen. Anti-RhD treatment is associated with mild to moderate 
infusion toxicities. Rare life-threatening toxicities such as hemoglobinuria, acute renal failure 
and disseminated intravascular coagulation have been reported. Recommendations have been 
proposed to reduce the risk of these complications. Anti-D immunoglobulin can be an effective 
option for rapidly increasing platelet counts in patients with symptomatic ITP.
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Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a 
decreased number of platelets that often results in mucocutaneous bleeding.1 ITP 
remains a diagnosis of exclusion. Although multiple associations have been recognized 
(secondary ITP), the etiology of idiopathic or primary ITP remains uncertain.1 ITP 
in adults typically has a remitting-relapsing course; while ITP in children typically 
occurs immediately after an infectious illness and most often resolves spontaneously, 
without further relapses.1,2 Secondary ITP has been associated with autoimmune 
disorders such as systemic lupus erythematosus, antiphospholipid antibody syndrome, 
or thyroid abnormalities, infections with human immunodeﬁ  ciency virus, hepatitis C, 
or Helicobacter pylori, and certain hematologic malignancies.3
Multiple mechanisms have been described in ITP, highlighting the heterogeneous 
nature of this disease.4 Anti-platelet auto-antibodies, directed against platelet mem-
brane glycoproteins have been identiﬁ  ed.4 Platelets coated with IgG auto-antibodies 
undergo rapid clearance through Fcγ receptors on tissue macrophages.4 Auto-antibodies 
may also induce megakaryocytic apoptosis resulting in defective platelet production.4 
Treatment of ITP targets different aspects of antibody-mediated platelet clearance, 
autoantibody production and/or immune-mediated defective platelet production.5Biologics: Targets & Therapy 2009:3 58
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Common ﬁ  rst-line treatments of ITP are intended to inhibit 
autoantibody-mediated platelet clearance. These would include 
the use of corticosteroids (such as prednisone, dexamethasone), 
intravenous immunoglobulin (IVIg) and anti-RhD immuno-
globulin (anti-D).5 Other therapies may target autoantibody 
production as well as platelet clearance and can include 
splenectomy, danazol, azathioprine, cyclosphosphamide and 
anti-CD20 therapy with rituxamab.5 Recently, romiplostim, 
a thrombopoietin receptor agonist, has been approved for the 
treatment of refractory ITP.6 In this review we will focus on 
the use of anti-D immunoglobulin in the treatment of ITP.
Anti-RhD immunoglobulin
Anti-RhD immunoglobulin is composed of immunoglobulin 
G (IgG) prepared from the plasma of repeatedly immunized 
human RhD-negative donors. Anti-D IgG is manufactured 
from the plasma of donors and contains 90% polyclonal 
immunoglobulin G anti-D.7 The concentration of IgG1, IgG2, 
and IgG3 are comparable to those of normal serum while the 
levels of IgG4 are negligible.7,8 There are also minimal concen-
trations of antibodies against other red blood cell antigens.
Anti-RhD was originally prepared to prevent hemolytic 
disease in newborns.9 Since 1983, it has been used to treat 
patients with immune thrombocytopenia.9,10 In March of 1995, 
anti-D immunoglobulin was licensed by the United States 
Food and Drug Administration for the treatment of immune 
thrombocytopenic purpura in non-splenectomized children 
with acute ITP who were RhD-positive and children and adults 
with ITP secondary to human immunodeﬁ  ciency infection.8
History of clinical use
In 1984, Salama et al published the ﬁ  rst results on the use 
of intravenous anti-D in 10 Rh-positive ITP patients.9,10 The 
patients had chronic ITP with the duration of their disease 
ranging from 1 to 21 years. Nine patients were female, of 
whom 4 had previous splenectomy. They received an initial 
intravenous dose of 200 to 1000 μg of anti-D immunoglobulin 
for a total dose of 300 to 3600 μg. On average, the platelets 
increased by 80%. The platelet counts of splenectomized 
patients increased by 16 × 109/L while the average increase 
in non-splenectomized patients was 60 × 109/L. The increased 
platelet count lasted from 7 to over 150 days. A transient but 
mild hemolysis was observed in 7 of 10 patients.
Anti-D treatment in children
In 1986, Panzer et al compared the efﬁ  cacy of IVIg (0.4 g/kg × 
5 days) with anti-D (11–20 μg/kg × 5 days) in 5 patients with 
ITP, 2 of whom were children.11 The one child with acute 
ITP who received anti-D had a platelet increase of 11 × 109/L 
while the child with chronic ITP had a platelet increase of 
22 × 109/L. Neither child had a signiﬁ  cant decrease in their 
hemoglobin levels. In the same year, a collaborative study of 
15 Rh-positive children with ITP were treated with low-dose 
anti-D (28–50 μg/kg intravenously) was reported by Becker 
and colleagues.12 Ten patients had chronic ITP (duration of 
6–47 months), while 5 had acute ITP. All patients had resolu-
tion of their bleeding and increased in platelet counts without 
a signiﬁ  cant decrease in their hemoglobin or other adverse 
effects exclusive of minor transfusion related symptoms.12 In 
the children with chronic ITP the duration of the platelet count 
increase ranged from 10 to over 360 days.
In 1991, Bussel et al treated 46 patients with ITP, of which 
20 were children.13 Anti-D was given at a treatment dose of 
50 μg/kg.13 Of the 20 children, 14 had ITP for greater than 
6 months and 3 children were HIV-positive. Platelet increases 
were greater in children than adults (median 92 × 109/L versus 
26 × 109/L). Of the 14 children with chronic disease, 2 achieved 
remission and 3 became stable after 5 treatments.
Andrew et al performed a multicenter cohort study of 
escalating doses of intravenous anti-D in children with 
chronic ITP (greater than 6 months’ duration).14 Twenty-ﬁ  ve 
Rh-positive children received doses of anti-D that increased 
from 25 μg/kg upwards to 55 μg/kg. By day 7 of the protocol, 
23 patients had responded to therapy, 18 of whom had 
platelet counts greater than 150,000/μL. The median dura-
tion of response was 5 weeks (range 1 to 24 weeks). Of the 
23 responding patients, 21 were retreated and 18 responded 
to the second course of therapy. By the completion of the 
study, 16 patients continued to have excellent responses to 
intermittent anti-D therapy.
A randomized study of 146 children with acute ITP 
with platelet counts below 20,000/μL compared high dose 
IVIg (1 g/kg × 2 days or 0.8 g/kg × 1), intravenous anti-D 
(25 μg/kg × 2 days), or oral prednisone (4 mg/kg/day with 
tapering and discontinuation by day 21).15 The increase in 
platelets was signiﬁ  cantly faster for patients receiving IVIg 
compared to anti-D. The hemoglobin fell to less than 10 g/dL 
in 24% of the patients receiving anti-D. The authors were 
unable to recommend anti-D as initial therapy for children 
with acute ITP with platelet counts lower than 20,000/μL. 
Borgna-Pignatti et al published a series on 7 pediatric patients 
with chronic ITP who were treated with intramuscular 
anti-D for 5 times on an alternate-day basis.16 Five patients 
responded to therapy, 2 of whom went into long-term remis-
sion. No patient experienced signiﬁ  cant anemia despite 
evidence of low-grade hemolysis.Biologics: Targets & Therapy 2009:3 59
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In 1997, Scaradavou et al published the largest study 
of anti-D use in ITP patients.17 Two hundred seventy-
two patients were treated, including 124 children and 
137 adult chronic ITP patients, of which 105 patients 
(children and adults) were HIV-positive. An additional 
11 post-splenectomy patients were also treated. The patients 
received 25 or 50 μg/kg/dose of intravenous anti-D, with the 
post-splenectomy patients receiving 100–200 μg/kg/dose. 
The best treatment responses were observed in the HIV-
negative children. HIV-negative pediatric patients had a 
signiﬁ  cantly higher mean platelet increase (119,000 × 109/L) 
when compared to the HIV-infected children (65 × 109/L; 
p = 0.005). Also the number of responding HIV-negative 
children (83%) was signiﬁ  cantly greater than that observed 
in the HIV-negative adults (69%; p = 0.05). Anti-D therapy 
at doses given was again shown to be ineffective in patients 
who failed splectectomy. The inability of the drug to work in 
this patient population may reﬂ  ect of different pathophysiol-
ogy of the disease in splenectomy failures such a antibody 
mediated defective megakaryopoiesis.18
Anti-D treatment in adults
Immune thrombocytopenia in adults is most often chronic 
in nature. Many patients, requiring multiple therapeutic 
interventions. Anti-D treatment, along with intravenous Ig, 
remains one of the few non-immunosuppressive therapies 
capable of acutely increasing platelet counts in patients with 
severe thrombocytopenia.
Two years following his 1984 publication, Salama 
reported a study of anti-D treatment in 17 adults patients 
with ITP (15 chronic ITP patients and 2 acute ITP).19 The 
patients were given intravenous and/or intramuscular injec-
tions of anti-D. An average increase in the platelet count of 
50 × 109/L was achieved in 13 of the Rh-positive patients 
and none of the Rh-negative patients.19 A long-term response 
of greater than 5 months was achieved in 5 patients. Overt 
hemolysis was observed in one patient.19 Rossi and colleagues 
treated 13 adult HIV-positive ITP patients with varying 
doses of anti-D.20 A mean platelet count increase to greater 
than 100 × 109/L was observed and response was associated 
with a decrease in the patients’ hemoglobin ranging between 
1 and 1.7 g/dL.
Boughton et al reported a study of 13 Rh-positive adult 
patients with chronic ITP who received varying intravenous 
doses of anti-D.21 Signiﬁ  cant increases in platelet counts were 
seen in all patients, especially those who received 12,500 IU 
of anti-D. No adverse effects were observed in the patient 
groups. In the same year, Oksenhendler examined the effects 
of intravenous anti-D (12–25 μg/kg × 2 days) on 17 adult 
HIV-positive ITP patients with platelet counts less than 
20 × 109/L.22 Nine patients (53%) had a signiﬁ  cant increase 
in their platelet counts to greater than 50 × 109/L.
In 1992, Gringeri et al performed a prospective study in 
51 ITP patients, 24 of whom were HIV-positive.23 Patients 
who responded to intravenous anti-D (3 μg/kg × 3 days) 
received intramuscular injections of anti-D (6 μg/kg/week). 
Twenty of the 24 HIV-positive ITP patients had a platelet 
response as opposed to 14 of the 27 idiopathic chronic ITP 
patients. In the same year, Rodeghiero et al published the 
results of 49 adult patients treated with high-dose IVIg or 
anti-D.24 Response and remission rates did not vary signiﬁ  -
cantly among the two groups.24
As mentioned earlier, the largest study to date was pub-
lished in 1997 by Scaradavou et al.17 In this study, 137 adult 
patients, including both HIV negative and positive patients, 
were treated with anti-D. In contrast to the results observed in 
the pediatric patients, HIV infection of adult ITP patients did 
not inﬂ  uence their response to anti-D. Baseline hemoglobin 
signiﬁ  cantly affected platelet response to anti-D in adults 
with the mean platelet increase (51 × 109/L versus 21 × 109/L) 
and response rate (72% versus 42%) signiﬁ  cantly higher in 
patients with hemoglobin levels 12 g/dL.
Dosing: 50 mg/kg versus 75 μg/kg
The approved dosing regimen for anti-D therapy in the 
United States is 50 μg/kg. However, signiﬁ  cant questions 
remain as to whether higher doses may be safe and more 
efﬁ  cacious. Newman and colleagues, reported on a random-
ized study comparing 75 μg/kg anti-D to the approved dose 
of 50 μg/kg.25 Previous studies reported that a maximal 
platelet response to 50 μg/kg/d occurred 72 hours after 
intravenous infusion. Twenty-seven adult, HIV-negative, 
non-splenectomized patients with initial platelet counts less 
than 30 × 109/L were studied. The 75 μg/kg/day dose resulted 
in greater median platelet increases on days 1 and 7, when 
compared with the 50 μg/kg dose, without a signiﬁ  cantly 
greater decrease in hemoglobin.25
Anti-D maintenance treatment 
to avoid or delay splenectomy:
Cooper et al examined whether repeated infusions of anti-D 
could allow adults ITP patients, who had failed initial corti-
costeroid therapy, avoid splenectomy.26 Twenty-eight adult 
patients with platelet counts of less than 30 × 109/L were 
repeatedly treated with anti-D whenever their platelet count 
decreased to less than 30 × 109/L. A response was deﬁ  ned as Biologics: Targets & Therapy 2009:3 60
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an incremental platelet increase greater than 20 × 109/L with an 
absolute value greater than 30 × 109/L within 7 days of therapy. 
Twenty-six (93%) patients responded to initial anti-D treatment 
and 19 patients (68%) responded to repeated treatments. After 
a median follow-up of 26 months, 19 patients avoided splenec-
tomy; including 12 (43%) patients who were off treatment for 
more than 6 months without requiring a splenectomy. At study 
entry, a platelet count greater than 14 × 109/L was a primary 
predictor for patients more likely to successfully discontinue 
treatment with anti-D.26
In a second randomized study to evaluate the use of anti-
D as an alternative to corticosteroid therapy in patients 
who wish to avoid or delay splenectomy, 70 patients were 
randomized to either anti-D or corticosteroid therapy. A 
splenectomy was to be performed if a patient failed to 
respond to 3 consecutive anti-D treatments given within 10 
days.27 Patients treated with repeat doses of anti-D were able 
to avoid splenectomy for a median duration of 112 days as 
opposed to 36 days in the corticosteroid treated group and 
required fewer days of corticosteroid therapy. However, 
splenectomy was performed prematurely against study pro-
tocol in 11of the 14 patients randomized to anti-D treatment 
and there was no statistical difference in the total number 
of patients in either treatment arm who subsequently had 
a splenectomy.27
Mechanisms
Multiple mechanisms whereby anti-D ameliorates thrombo-
cytopenia have been proposed, including mononuclear phago-
cytic system (MPS) blockade, and cytokine modulation.28–30
The largest body of evidence exists for the competitive 
inhibition and blockade of the mononuclear phagocytic 
system by sensitized red blood cells within the spleen. 
Evidence to support this as a major mechanism of the 
therapy include multiple studies which show that anti-D 
is ineffective in RhD antigen-negative patients and rela-
tively ineffective at standard doses in patients who have 
had a splenectomy. In vitro studies of cytokine expres-
sion from human monocytes and granulocytes exposed to 
anti-D coated red blood cells have demonstrated enhanced 
secretion of interleukin 1 receptor antagonist resulting in 
down-regulation of FcγR mediated phagocytosis.28 Murine 
models of ITP have demonstrated that RBC-speciﬁ  c anti-
bodies can increase platelet counts by down-regulating 
FcγRIIIa on splenic macrophage in a manner dissimilar 
to IVIg.29
A study evaluating the cytokine responses to infusions of 
IVIg and anti-D in patients with ITP demonstrated signiﬁ  cant 
increases in interleukin 6 and 10, monocyte chemo-attractant 
protein-1, and tumor necrosis factor α within 2 hours of infu-
sion of anti-D.30 Higher levels of Il-10 correlated with the 
greatest platelet increases at 24 hours. Patients with FcγIIa-
131HH genotype had higher cytokine responses and patients 
with FcγIIIa-158VF had higher platelet counts by day 7.30 
It would appear from these studies that anti-D therapy induces 
an initial inﬂ  ammatory cytokine response mediated through 
the FcγIIa receptor leading to a secondary suppression of 
FcγRIIIa mediated platelet phagocytosis. This is signiﬁ  cantly 
different from the anti-inﬂ  ammatory effect of IVIG in which 
FcγIIIa and FcγIIa receptors are down-regulated by interac-
tion of IVIG with FcγIIB receptors.28–31
Toxicities associated 
with anti-D treatment
In the original anti-D IGIV clinical trials for ITP, 2 cases 
of acute onset hemoglobinuria consistent with intravascular 
hemolysis were noted.32 Additional cases of acute hemoglobi-
nemia and hemoglobinuria have subsequently been reported 
to the FDA.33 In April of 1998, the manufacturers of anti-D 
revised the package insert to include reports of hemoglobin-
uria that was occasionally accompanied by reversible, acute 
renal impairment.8
Gaines reviewed 11 patient reports of hemoglobinuria and 
noted that 7 of these patients developed signiﬁ  cant anemia 
that required packed red blood cell transfusion orders.33 Eight 
patients experienced new onset or an exacerbation of pre-
existing renal insufﬁ  ciency and 2 patients required dialysis. 
One patient died from pulmonary edema and respiratory 
distress associated with exacerbated anemia. The authors 
conjectured several possible mechanisms, including concom-
itant disorders associated with immune-mediated hemolysis 
such as undiagnosed Evan’s syndrome; Rh phenotype with 
high expression of D antigen; splenic saturation and resulting 
diminished capacity for clearance of anti-D-sensitized RBCs; 
the formation of complement ﬁ  xing immune complexes in 
vivo involving anti-D IgG1 or IgG3 aggregates with anti-
idiotype antibodies in anti-D immunoglobulin that bind to 
the red cell initiating complement-mediated hemolysis; or 
improper storage and reconstitution techniques of anti-D.33
Gaines subsequently published a review of dissemi-
nated intravascular coagulation (DIC) reported to the 
FDA following anti-D administration.34 This case series 
included 6 patients, 1 child and 5 adults, all of whom 
died. Gaines conjectured the DIC was causally related 
to hemoglobinemia and perhaps associated with the 
passive acquisition of blood group antibodies in anti-D Biologics: Targets & Therapy 2009:3 61
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immunoglobulin preparation, including high-titer anti-D, 
low-titer anti-A, anti-B, anti-C, anti-E, anti-Duffy, and 
anti-Kidd antibodies.34
In a letter to the editor, Tarantino et al proposed a “2-hit” 
phenomenon responsible for the intravascular hemolysis, 
DIC, and the renal failure sometimes seen after anti-D 
administration.35 Conditions that could have contributed to 
these complications with anti-D treatment include coexisting 
autoimmune hemolytic anemia (Evan’s syndrome), antiphos-
pholipid antibodies, pre-existing renal insufﬁ  ciency, and 
high cytokine induced hemostatic activation.35 The authors 
of the letter recommended examining for hematuria and 
hemoglobinuria 48 hours after anti-D infusion, screening 
for and avoiding use of the drug in patients with evidence of 
possible underlying hemolysis as suggested by an elevated 
reticulocyte count, and in patients at high risk for hemolysis 
such as those with positive direct red blood cell antibody 
test results.35
Summary
Anti-D immunoglobulin therapy has demonstrated efﬁ  cacy 
in rapidly increasing the platelet counts in nearly 80% of 
children and 70% of adults with ITP. It appears to be effective 
only in patients with an intact spleen. However, anecdotal 
reports of efﬁ  cacious use in splenectomized patients suggest 
the there may be some utility in selected patients. A more 
systematic study of its use in splenectomized patients may 
be indicated. While a higher dose of 75 μg/kg has shown in 
one study to result in a more rapid increase in the platelet 
count, it is uncertain whether this increase in the rate of 
response is of signiﬁ  cant clinical beneﬁ  t. Anti-D therapy 
appears to have signiﬁ  cant advantages over the use of intra-
venous immunoglobulin in regards to expense and a longer 
duration of response.17 While intermittent use of anti-D 
can be used to delay time to splenectomy in patients with 
chronic ITP, it does not appear to change the natural history 
of this disorder. It can allow for time for a small number of 
patients (15%) developing a spontaneous remission prior to 
splenectomy. However, it is uncertain whether use of the 
newer thrombopoietin receptor agonists could accomplish 
the same delay in splenectomy with less toxicity.6 Finally, 
while severe and life-threatening toxicities are rare with 
anti-D therapy, recent recommended guidelines for its use 
can reduce the risk of these serious events.35 Recombinant 
monoclonal and polyclonal anti-D antibodies have begun to 
be tested for autologous red cell clearance and a determina-
tion of their utility in the management of ITP awaits the 
results of further clinical studies.36–37
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